Answers are grounded in this paper and cite their sources.
Observational study reveals rising interest in dietary supplements across plasma cell disorders, highlighting the demand for integrative supportive care alongside standard treatment.
As novel treatments have improved survival in patients with plasma cell disorders (PCDs), there is a growing interest in complementary medicine (CM), particularly dietary supplements (vitamins, minerals, antioxidants, and herbs), amongst patients with cancer [ 1 ]. Multiple myeloma (MM) and its precursor conditions (monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)) provide opportunities for CM, as the standard practice for precursor conditions is observation while MM requires long term treatment – during which supportive strategies may improve treatment tolerance, response, and quality of life [ 2 ].
No takes yet. Share an insight, caveat, or question.
Malik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: